← Leaderboards

Nina Bhardwaj

Rockefeller University

Google Scholar ↗PubMed ↗ORCID ↗

$33,867,850

Attributed

$38,283,887

Total exposure

29

Grants

22

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.3M · FY2005–25

$5M$3.8M$2.5M$1.3M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$38,283,887 · 29

By mechanism

R01$19,056,692 · 8

U19$6,819,288 · 1

R37$4,242,628 · 1

K12$1,998,160 · 1

P01$1,918,766 · 3

UG3$1,672,056 · 1

Top collaborators

Most similar at Rockefeller University

Same institution · by research overlap

Megan C King$5,759,172

Others in their field

Top investigators on “Dendritic Cells”

Barton F Haynes · Duke University$112,608,041
Constance Ann Benson · University Of California, San Diego$65,790,143
David Heimbrook · Leidos Biomedical Research, Inc.$56,453,265
James C. Paulson · Scripps Research Institute$41,568,802
Ulrich H Von Andrian · Harvard Medical School$32,521,007
Donald L Morton · John Wayne Cancer Institute$29,042,629

Research focus

Dendritic CellsCellsT-LymphocyteResponseImmune ResponseImmuneImmunityBaseMalignant NeoplasmsAntigensClinical TrialsIn VitroLaboratoriesProgramsMediatingPathway InteractionsClinical ResearchTumorImmunotherapyResearch PersonnelHiv InfectionsAntigen-Presenting CellsCell PhysiologyCytokine

Grant awards (110)

Immune determinants modulating cancer development in Lynch Syndrome$836,028

UG3 · FY2025 · CA · contact PI

The Tisch Cancer Institute (TCI) Paul Calabresi K12 Career Development Award for Clinical Oncology$666,985

K12 · FY2025 · CA · contact PI

Cancer Immunology$28,000

P30 · FY2025 · CA · contact PI

Immune determinants modulating cancer development in Lynch Syndrome$836,028

UG3 · FY2024 · CA · contact PI

The Tisch Cancer Institute (TCI) Paul Calabresi K12 Career Development Award for Clinical Oncology$710,306

K12 · FY2024 · CA · contact PI

Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer$668,229

R01 · FY2024 · CA · contact PI

Cancer Immunology$26,344

P30 · FY2024 · CA · contact PI

Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer$689,332

R01 · FY2023 · CA · contact PI

The Tisch Cancer Institute (TCI) Paul Calabresi K12 Career Development Award for Clinical Oncology$566,869

K12 · FY2023 · CA · contact PI

Cancer Immunology$26,344

P30 · FY2023 · CA · contact PI

Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer$689,329

R01 · FY2022 · CA · contact PI

The Tisch Cancer Institute (TCI) Paul Calabresi K12 Career Development Award for Clinical Oncology$54,000

K12 · FY2022 · CA · contact PI

Cancer Immunology$26,344

P30 · FY2022 · CA · contact PI

Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer$703,400

R01 · FY2021 · CA · contact PI

Exposing virus-induced long noncoding RNA in plasmacytoid dendritic cells$423,750

R01 · FY2021 · AI · contact PI

Cancer Immunology$26,344

P30 · FY2021 · CA · contact PI

Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer$703,400

R01 · FY2020 · CA · contact PI

Exposing virus-induced long noncoding RNA in plasmacytoid dendritic cells$423,750

R01 · FY2020 · AI · contact PI

NK cell exhaustion in metastatic melanoma$387,731

R01 · FY2020 · CA · contact PI

Effect of SARS-CoV-2 on clinical course and NK cells in patients receiving immunotherapy$168,429

R01 · FY2020 · CA · contact PI

Cancer Immunology$26,344

P30 · FY2020 · CA · contact PI

Exposing virus-induced long noncoding RNA in plasmacytoid dendritic cells$423,750

R01 · FY2019 · AI · contact PI

NK cell exhaustion in metastatic melanoma$376,099

R01 · FY2019 · CA · contact PI

Cancer Immunology (CI) (Project-001)$13,687

P30 · FY2019 · CA · contact PI

Exposing virus-induced long noncoding RNA in plasmacytoid dendritic cells$423,750

R01 · FY2018 · AI · contact PI

NK cell exhaustion in metastatic melanoma$387,731

R01 · FY2018 · CA · contact PI

Matrix metalloproteinase-2 modulates inflammation via TLR2$351,713

R01 · FY2018 · CA · contact PI

Cancer Immunology (CI) (Project-001)$15,129

P30 · FY2018 · CA · contact PI

Exposing virus-induced long noncoding RNA in plasmacytoid dendritic cells$423,750

R01 · FY2017 · AI · contact PI

NK cell exhaustion in metastatic melanoma$387,731

R01 · FY2017 · CA · contact PI

Matrix metalloproteinase-2 modulates inflammation via TLR2$351,713

R01 · FY2017 · CA · contact PI

Cancer Immunology (CI) (Project-001)$15,129

P30 · FY2017 · CA · contact PI

NK cell exhaustion in metastatic melanoma$403,630

R01 · FY2016 · CA · contact PI

Matrix metalloproteinase-2 modulates inflammation via TLR2$351,713

R01 · FY2016 · CA · contact PI

Cancer Immunology (CI) (Project-001)$15,130

P30 · FY2016 · CA · contact PI

Modulating anti-HIV immunity by plasmacytoid dendritic cells$416,289

R01 · FY2015 · AI · contact PI

Matrix metalloproteinase-2 modulates inflammation via TLR2$351,713

R01 · FY2015 · CA · contact PI

Cancer Immunology (CI) (Project-001)$9,293

P30 · FY2015 · CA · contact PI

Matrix metalloproteinase-2 modulates inflammation via TLR2$351,713

R01 · FY2014 · CA · contact PI

Modulating anti-HIV immunity by plasmacytoid dendritic cells$338,604

R01 · FY2014 · AI · contact PI

Induction of Immunity by Non-Replicating HIV-1$221,216

R37 · FY2014 · AI · contact PI

Modulating anti-HIV immunity by plasmacytoid dendritic cells$393,141

R01 · FY2013 · AI · contact PI

Induction of Immunity by Non-Replicating HIV-1$271,747

R37 · FY2013 · AI · contact PI

Induction of Immunity by Non-Replicating HIV-1$24,703

R37 · FY2013 · AI · contact PI

Modulating anti-HIV immunity by plasmacytoid dendritic cells$418,275

R01 · FY2012 · AI · contact PI

Induction of Immunity by Non-Replicating HIV-1$322,240

R37 · FY2012 · AI · contact PI

Vaccine Facility$90,543

P30 · FY2012 · CA · contact PI

Melanoma$30,980

P30 · FY2012 · CA · contact PI

Innate Discovery Team$1,204,043

U19 · FY2011 · AI · contact PI

Modulating anti-HIV immunity by plasmacytoid dendritic cells$418,275

R01 · FY2011 · AI · contact PI

Modulating Immunity through Dendritic Cell Phagocytic Receptors$415,317

R01 · FY2011 · AI · contact PI

Induction of Immunity by Non-Replicating HIV-1$332,798

R37 · FY2011 · AI · contact PI

NIAID Clinical Trial Planning Grant$286,050

R34 · FY2011 · AI · contact PI

Vaccine Facility$89,444

P30 · FY2011 · CA · contact PI

Melanoma$23,253

P30 · FY2011 · CA · contact PI

Innate Discovery Team$1,290,392

U19 · FY2010 · AI · contact PI

Immunosuppressive pathways in acute HIV infection$493,625

RC1 · FY2010 · AI · contact PI

Modulating anti-HIV immunity by plasmacytoid dendritic cells$422,500

R01 · FY2010 · AI · contact PI

Modulating Immunity through Dendritic Cell Phagocytic Receptors$419,513

R01 · FY2010 · AI · contact PI

Induction of Immunity by Non-Replicating HIV-1$308,187

R37 · FY2010 · AI · contact PI

Vaccine Facility$94,151

P30 · FY2010 · CA · contact PI

Melanoma$24,476

P30 · FY2010 · CA · contact PI

Innate Discovery Team$1,385,755

U19 · FY2009 · AI · contact PI

Immunosuppressive pathways in acute HIV infection$465,500

RC1 · FY2009 · AI · contact PI

Modulating Immunity through Dendritic Cell Phagocytic Receptors$423,750

R01 · FY2009 · AI · contact PI

Induction of Immunity by Non-Replicating HIV-1$361,112

R37 · FY2009 · AI · contact PI

Induction of Immunity by Non-Replicating HIV-1$338,150

R37 · FY2009 · AI · contact PI

Vaccine Facility$97,701

P30 · FY2009 · CA · contact PI

Melanoma$25,400

P30 · FY2009 · CA · contact PI

Innate Discovery Team$1,374,011

U19 · FY2008 · AI · contact PI

Dendritic Cell mediated induction of Anti-HCV immunity$571,176

R01 · FY2008 · AI · contact PI

Induction of Immunity by Non-Replicating HIV-1$456,510

R37 · FY2008 · AI · contact PI

Modulating Immunity through Dendritic Cell Phagocytic Receptors$423,541

R01 · FY2008 · AI · contact PI

Dendritic cells and primary HIV infection$405,435

P01 · FY2008 · AI · contact PI

Vaccine Facility$55,546

P30 · FY2008 · CA · contact PI

Melanoma$14,441

P30 · FY2008 · CA · contact PI

DENDRITIC CELLS VERSUS MONTANIDE TO STIMULATE ANTI-TUMOR IMMUNITY IN MELANOMA$447

M01 · FY2008 · RR · contact PI

Innate Discovery Team$1,565,087

U19 · FY2007 · AI · contact PI

Dendritic Cell mediated induction of Anti-HCV immunity$567,063

R01 · FY2007 · AI · contact PI

Induction of Immunity by Non-Replicating HIV-1$463,251

R37 · FY2007 · AI · contact PI

Dendritic cells and primary HIV infection$430,462

P01 · FY2007 · AI · contact PI

DENDRITIC CELLS VERSUS MONTANIDE TO STIMULATE ANTI-TUMOR IMMUNITY IN MELANOMA$15,780

M01 · FY2007 · RR · contact PI

Dendritic Cell mediated induction of Anti-HCV immunity$583,096

R01 · FY2006 · AI · contact PI

Induction of Immunity by Non-Replicating HIV-1$474,995

R37 · FY2006 · AI · contact PI

Dendritic cells and primary HIV infection$439,450

P01 · FY2006 · AI · contact PI

DENDRITIC CELLS VERSUS MONTANIDE TO STIMULATE ANTI-TUMOR IMMUNITY IN MELANOMA$5,144

M01 · FY2006 · RR · contact PI

Dendritic Cell mediated induction of Anti-HCV immunity$591,583

R01 · FY2005 · AI

Dendritic cells and primary HIV infection$426,131

P01 · FY2005 · AI

Induction of Immunity by Non-Replicating HIV-1$422,500

R37 · FY2005 · AI

Plasmacytoid Dendritic Cells and Anti-HIV Responses$253,500

R21 · FY2005 · AI

Induction of Immunity by Non-Replicating HIV-1$33,969

R37 · FY2005 · AI

Dendritic Cell mediated induction of Anti-HCV immunity$592,049

R01 · FY2004 · AI

Plasmacytoid Dendritic Cells and Anti-HIV Responses$253,500

R21 · FY2004 · AI

Dendritic cells and primary HIV infection$217,288

P01 · FY2004 · AI

Induction of Immunity by Non-Replicating HIV-1$211,250

R37 · FY2004 · AI

Role of Human Dendritic Cells in Lymphocyte Activation$28,728

M01 · FY2004 · RR

IN VIVO INDUCTION OF HIV SPECIFIC CTL BY DENDRITIC CELLS$840,253

R01 · FY2003 · AI

IN VIVO INDUCTION OF HIV SPECIFIC CTL BY DENDRITIC CELLS$693,106

R01 · FY2002 · AI

IMMUNITY TO ANTIGEN BEARING DENDRITIC CELLS IN VOLUNTEERS$0

M01 · FY2002 · RR

P01 · FY2002 · CA

Cross presentation of melanoma antigens by dendritic cells$0

P01 · FY2002 · CA

IN VIVO INDUCTION OF HIV SPECIFIC CTL BY DENDRITIC CELLS$408,119

R01 · FY2001 · AI

P01 · FY2001 · CA

Cross presentation of melanoma antigens by dendritic cells$0

P01 · FY2001 · CA

IMMUNITY TO ANTIGEN BEARING DENDRITIC CELLS IN VOLUNTEERS$0

M01 · FY2001 · RR

IN VIVO INDUCTION OF HIV SPECIFIC CTL BY DENDRITIC CELLS$395,612

R01 · FY2000 · AI

INDUCTION OF HUMAN CTL RESPONSES BY DENDRITIC CELLS$283,074

R01 · FY2000 · AI

Cross presentation of melanoma antigens by dendritic cells$0

P01 · FY2000 · CA

P01 · FY2000 · CA

IMMUNITY TO ANTIGEN BEARING DENDRITIC CELLS IN VOLUNTEERS$0

M01 · FY2000 · RR